Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

View ORCID ProfileJean-François Rossignol, Matthew C. Bardin, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, View ORCID ProfileChristian Bréchot, for the Vanguard Study Group
doi: https://doi.org/10.1101/2021.04.19.21255441
Jean-François Rossignol
1Romark Institute of Medical Research, Tampa, Florida
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-François Rossignol
Matthew C. Bardin
1Romark Institute of Medical Research, Tampa, Florida
PharmD, BCPS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: matthew.bardin@romark.com
Joshua B. Oaks
2Progressive Clinical Research, Bountiful, Utah
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Gregory Bostick
3Cullman Clinical Trials, Cullman, Alabama
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kishor N. Vora
4Research Integrity, LLC, Owensboro, Kentucky
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Fulgencio
1Romark Institute of Medical Research, Tampa, Florida
MBA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dena Mogelnicki
1Romark Institute of Medical Research, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Bréchot
1Romark Institute of Medical Research, Tampa, Florida
5University of South Florida, College of Medicine, Tampa, Florida
6Global Virus Network
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Bréchot
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization.

Methods This is a double-blind randomized multicenter study in 36 centers in the U.S. and Puerto Rico investigating the potential of a five-day treatment with nitazoxanide 300 mg extended release tablets in 379 outpatients with mild or moderate laboratory-confirmed COVID-19 with an onset of symptoms no more than 72 hours before inclusion. Key objectives were reduction of duration of symptoms (primary), progression to severe illness (key secondary), hospitalization and viral load.

Results Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction in the progression to severe COVID-19 (1/184, [0.5%] nitazoxanide vs. 7/195, [3.6%] placebo). In subjects at high-risk according to CDC criteria, 1/112 (0.9%) of nitazoxanide-treated subjects and 7/126 (5.6%) of placebo-treated subjects experienced progression to severe COVID-19. Treatment led to a 79% reduction in the rate of hospitalization (1/184 [0.5%] nitazoxanide vs. 5/195 [2.6%] placebo). The proportions positive for SARS-CoV-2 RNA and viral load at days 4 and 10 were not reduced. Nitazoxanide was safe and well tolerated.

Conclusions Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85% reduction in the progression to severe illness.

Competing Interest Statement

Jean-Francois Rossignol is an employee of and owns equity interest in Romark, L.C. Mathew Bardin, Jessica Fulgencio and Dena Mogelnicki are employees of Romark, L.C.; Christian Brechot is a senior adviser for Romark, L.C., an adviser for the Theravectys, Shanghai Vivo Biosciences and the chairman of The Healthy Aging company.

Clinical Trial

NCT04486313

Funding Statement

This study was funded by the Romark Institute of Medical Research.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IntegReview IRB 3815 S. Capital of Texas Highway Suite 320 Austin, Texas 78704

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵* Members of the study group are listed in the Appendix

Data Availability

Reasonable requests from qualified researchers will be considered for data sharing. These requests should be submitted to medinfo@romark.com.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 20, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Jean-François Rossignol, Matthew C. Bardin, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot, for the Vanguard Study Group
medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Jean-François Rossignol, Matthew C. Bardin, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot, for the Vanguard Study Group
medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (658)
  • Epidemiology (10796)
  • Forensic Medicine (8)
  • Gastroenterology (589)
  • Genetic and Genomic Medicine (2946)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1927)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (291)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12515)
  • Intensive Care and Critical Care Medicine (688)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2798)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1463)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2639)
  • Public and Global Health (5363)
  • Radiology and Imaging (1011)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)